Clinical Oncology Next Generation Sequencing: Critical Driver Shaping the Cancer Incidence And Its Impact On The Clinical Oncology Next-Generation Sequencing Market Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Clinical Oncology Next Generation Sequencing Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Significant expansion has been observed in the clinical oncology next generation sequencing market in the past few years. This market is anticipated to increase from a value of $0.51 billion in 2024 to approximately $0.58 billion in 2025, boasting a compound annual growth rate (CAGR) of 13.9%. This progression during the historic timespan is tied to enhancements in genomic research, the discovery of cancer biomarkers, technological evolution, alongside regulatory clearances.

Clinical Oncology Next Generation Sequencing Market Size Forecast: What's the Projected Valuation by 2029?
The next generation sequencing market for clinical oncology is projected to experience significant expansion in the upcoming years, escalating to a value of $0.94 billion in 2029 with a CAGR of 12.7%. This surge in growth during the forecasted period can be ascribed to factors such as the increasing prevalence of cancer, precision medicine, immuno-oncology, and liquid biopsies. In the same forecasted period, key trends to watch out for would include extensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, as well as AI and machine learning.

View the full report here:
https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Drivers Transforming the Clinical Oncology Next Generation Sequencing Market?
The global increase in cancer diagnoses is anticipated to drive the expansion of the clinical oncology next-generation sequencing market within the forecast timeframe. To illustrate, the National Cancer Institute, a government agency based in the US, reported that there were approximately 18.1 million cancer survivors in the US as of May 2024. This statistic is expected to ascend to 22.5 million by 2032. By 2040, the projected number of new cancer cases annually is anticipated to hit 29.9 million, with death tolls from cancer predicting to surge to 15.3 million. Consequently, the escalating rate of global cancer incidence is expected to stimulate the demand and subsequent growth of the clinical oncology next-generation sequencing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Clinical Oncology Next Generation Sequencing Market?
Leading organizations in the clinical oncology next-generation sequencing sector are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market profitability. Valued greatly by clinical laboratories engaged in cancer diagnostics and research, this system provides accuracy and efficacy in diagnostic tests, thereby bolstering patient care standards. For example, in June 2022, Roche, a pharmaceutical company from Switzerland, rolled out the BenchMark ULTRA PLUS system. This is their most advanced tissue staining platform, assisting healthcare professionals in determining patient treatment plans quickly and accurately, due to the system's swift and precise test results.

Which Segments in the Clinical Oncology Next Generation Sequencing Market Offer the Most Profit Potential?
The clinical oncology next generation sequencing market covered in this report is segmented -

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Firms Dominate the Clinical Oncology Next Generation Sequencing Market by Market Share and Revenue in 2025?
Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Which Regions Offer the Highest Growth Potential in the Clinical Oncology Next Generation Sequencing Market?
North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.